🏢 What kind of company is InMode?

InMode is an Israel-based aesthetics medical-device company that develops radiofrequency (RF) and laser platforms for non-invasive and minimally invasive procedures. It supplies devices used in plastic surgery and dermatology practices worldwide, building a solid position in the medical aesthetics field.

Its core business is the development and sale of medical-device platforms for body contouring, skin rejuvenation, and wrinkle and fat reduction. The company offers equipment at competitive price points and then generates recurring revenue from consumables such as treatment tips, giving it a differentiated position in the aesthetics medical-device market.

💰 How does InMode make money?

Revenue is led by capital-equipment sales, while disposable applicators consumed with each procedure add recurring income that scales with the installed base. The consumables mix has been gradually expanding, and as more systems are placed in the field, revenue stability strengthens. A global sales network spanning North America, Europe, Asia-Pacific, and Latin America supports regional diversification, with aesthetics-procedure demand and new-product launch cycles acting as growth drivers. The combination of equipment and consumables supports margin stability.

📐 InMode market cap and company size

Market capitalization stands at $856.5M with an employee base of 660 people.

InMode is positioned as a small- to mid-sized specialist company within the global medical aesthetics-device market. The aesthetics-device market is projected to grow steadily, and InMode is focused on the high-growth non-surgical procedure segment. Among industry peers, it is commonly benchmarked alongside aesthetics-device peer ESTA, clear-aligner leader ALGN, and ophthalmology/aesthetics-adjacent device maker STAA within the medical-device theme.

📈 InMode outlook and stock trends

In the near term, consumer spending, aesthetics-procedure demand, and capital-equipment investment cycles among medical providers are key earnings variables. Over the medium to long term, expanding demand for non-invasive procedures, new platform launches, and the cumulative effect of recurring consumable revenue can serve as growth drivers. However, intensifying competition, FX volatility, and region-specific regulatory environments remain potential sources of volatility, and new-product momentum and the pace of installed-base expansion are likely to dictate the trajectory going forward.

⚔️ InMode key strengths and risks

Strengths include the recurring-revenue model combining equipment and consumables and a focused position in the non-surgical aesthetics market, while risks include intensifying competition and cyclical capital-equipment demand.

🔄 InMode competitors and related (beneficiary) stocks

On the direct-competition side, aesthetics and reconstructive medical-device peer ESTA is benchmarked within the same medical-device space. Related names include clear-aligner platform ALGN, ophthalmology/aesthetics-adjacent medical-device maker STAA, and large-cap pharma ABBV, which carries aesthetics businesses such as Botox and fillers, all grouped together under the medical-aesthetics theme. InMode's specialization in non-surgical devices is its key differentiator.

✅ Investor checklist for InMode

When reviewing InMode, it is useful to look at the balance between equipment sales and recurring consumable revenue, the new-product launch cadence, and demand trends across global markets. Understanding the structural characteristics of the aesthetics medical-device industry helps in interpreting earnings volatility.

Intensifying competition, the cyclical sensitivity of capital-equipment demand, regional regulations, and FX volatility are the main risks. If new-product momentum slows or installed-base expansion decelerates, revenue growth could come under pressure.

InMode is an aesthetics medical-device company distinguished by its recurring-revenue model and its focus on the non-surgical aesthetics market. Taking competition and demand volatility into account, the recommended approach is to monitor new-product momentum and the trajectory of consumable revenue.